RecruitingNot ApplicableNCT06718426

Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient.

Evaluation of Fertitonex Effects on Semen Parameters in Clinical Varicocele Patient, Placebo Controlled Study


Sponsor

Menoufia University

Enrollment

110 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of the study is to evaluate the Fertitonex effects on semen parameters in clinical varicocele patients.


Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria3

  • Primary infertility.
  • Abnormal semen analysis parameters.
  • Clinically evident varicocele confirmed by scrotal duplex.

Exclusion Criteria4

  • ry infertility.
  • Normal semen analysis parameters.
  • Clinically non-evident varicocele.
  • Past history of varicocelectomy.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFertitonex capsule

Fertitonex which contains L- carnitine L-tartarate 300 mg, L-arginine 241mg, vitamin B6 1.1 mg, vitamin B12 1.7 mcg, vitamin D3 2 mcg, vitamin E 6.5 mg, vitamin C 60 mg, selenium 28 mcg, zinc 7.5 mg, folic acid 300 mcg and CoQ 10 enzyme 7.5 mg in each capsule. The dose will be one capsule twice daily for 3 months.

DRUGPlacebo Oral Capsule

placebo oral capsule. the dose is twice daily for 3 months


Locations(1)

Menoufia Faculty of Medicine

Shebin El-Kom, Menoufia, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06718426


Related Trials